Richard Gonzalez, AP Images

House com­mit­tee un­cov­ers how Hu­mi­ra’s price spiked by 470% as Ab­b­Vie ex­ecs cashed bonus­es tied to the hikes

Pri­or to the House Com­mit­tee on Over­sight’s grilling of Ab­b­Vie CEO Richard Gon­za­lez on Tues­day, the com­mit­tee staff re­leased a 57-page re­port fol­low­ing a two year in­ves­ti­ga­tion in­to how and why the com­pa­ny spiked the price of Hu­mi­ra (adal­i­mum­ab) and made it the high­est-gross­ing drug of all time.

While the com­mit­tee in­ves­ti­ga­tion and pub­lic lash­ing aren’t like­ly to do ac­tu­al dam­age to Ab­b­Vie’s bot­tom line or bring new Hu­mi­ra biosim­i­lar com­pe­ti­tion be­fore 2023 in the US, the re­port digs in­to how Ab­b­Vie used more than two dozen price in­creas­es, shad­ow pric­ing with Am­gen’s block­buster En­brel, and patent thick­ets to block com­pe­ti­tion while amass­ing more than $170 bil­lion in net rev­enue from Hu­mi­ra since 2003.

Reps. Car­olyn Mal­oney (D-NY), chair of the Over­sight Com­mit­tee, Jar­rold Nadler (D-NY), chair of the House Ju­di­cia­ry Com­mit­tee, and sub­com­mit­tee chair David Ci­cilline (D-RI) al­so sent a let­ter to the Fed­er­al Trade Com­mis­sion on Tues­day, call­ing for a for­mal in­quiry in­to Ab­b­Vie’s ac­tions to de­lay the en­try of Hu­mi­ra biosim­i­lars in the US (more on the de­lays be­low).

Price In­creas­es

Near­ly a decade af­ter Ab­bott Lab­o­ra­to­ries first launched Hu­mi­ra in 2003, the list price rose from $522 per 40-mil­ligram sy­ringe to $1,024 by 2013, with 13 price hikes, pri­or to spin­ning off Ab­b­Vie as a sep­a­rate com­pa­ny. Un­der Ab­b­Vie, the price of Hu­mi­ra spiked an­oth­er 14 times, in­clud­ing by 30% with­in a 10-month win­dow.

“Hu­mi­ra is now priced at $2,984 per sy­ringe, or $77,586 an­nu­al­ly — a 470% in­crease from when the drug en­tered mar­ket,” the re­port says.

And those con­sis­tent price hikes were dri­ven by ex­ec­u­tive bonus­es from 2015 to 2018, which were di­rect­ly linked to Hu­mi­ra’s fi­nan­cial per­for­mance, the re­port says.

In that first year that the in­cen­tives were cre­at­ed, ex­ecs pushed Hu­mi­ra’s US net rev­enue to rise from $6.5 bil­lion in 2014 to $8.4 bil­lion in 2015, af­ter Ab­b­Vie ex­ec­u­tives im­ple­ment­ed a 9.9% price in­crease in April 2015 — the largest-ever price in­crease for the drug — and a 7.9% price in­crease in Au­gust 2015.

While Gon­za­lez will like­ly tell Con­gress Tues­day that the price in­creas­es were used to fund more re­search & de­vel­op­ment, the com­mit­tee shows that wasn’t the case.

“Ab­b­Vie’s to­tal re­search and de­vel­op­ment ex­pen­di­tures for Hu­mi­ra rep­re­sent­ed on­ly a small frac­tion of its net rev­enue from this drug. In re­sponse to the Com­mit­tee’s re­quest, Ab­b­Vie iden­ti­fied a to­tal of $5.19 bil­lion in ‘Hu­mi­ra Re­search & De­vel­op­ment’ be­tween 2009 and 2018 — ap­prox­i­mate­ly 7.4% of its Hu­mi­ra U.S. net rev­enue and 4.2% of its Hu­mi­ra world­wide net rev­enue over that pe­ri­od,” the re­port shows.

What the US would’ve saved

The re­port al­so tracks how much the US gov­ern­ment could’ve saved over­all by fac­tor­ing in some of the dis­counts that some fed­er­al de­part­ments re­ceive. Over­all, Ab­b­Vie’s Hu­mi­ra net rev­enue from Medicare — a fig­ure that sub­tracts dis­counts and re­bates— was $9.9 bil­lion from 2010 to 2018.

“If Medicare had re­ceived the same dis­counts as the De­part­ment of De­fense, it would have saved more than $7.4 bil­lion on Hu­mi­ra from 2010 to 2018. Sim­i­lar­ly, if Medicare had re­ceived the same dis­counts as the De­part­ment of Vet­er­ans Af­fairs, it would have saved $7 bil­lion on Hu­mi­ra from 2010 to 2018,” the re­port notes.

Re­pub­li­cans in Con­gress have fo­cused their at­ten­tion less on low­er­ing drug prices and more on low­er­ing out-of-pock­et costs, the re­port re­veals how out-of-pock­et costs for Hu­mi­ra have spiked too.

A 2019 Kaiser Fam­i­ly Foun­da­tion study found that the me­di­an an­nu­al out-of-pock­et cost for Medicare pa­tients on Hu­mi­ra was $5,471 in 2019, which is $606 more than in 2016.

A re­tired teacher and Medicare ben­e­fi­cia­ry with Crohn’s dis­ease told the com­mit­tee that de­spite hav­ing a sup­ple­men­tal health in­sur­ance plan, her out-of-pock­et costs for Hu­mi­ra were more than $2,600 for a month’s sup­ply, pre­vent­ing her from re­ceiv­ing treat­ment.

Rock­ford, Illi­nois May­or Tom Mc­Na­ma­ra al­so re­port­ed that be­tween Au­gust 2013 and Ju­ly 2020, his city spent more than $2.5 mil­lion on Hu­mi­ra alone, which means more than 5% of the city’s em­ploy­ee health plan ex­pen­di­tures were for Hu­mi­ra.

Don’t blame the play­er, blame the game?

In ad­di­tion to rais­ing the price, Ab­b­Vie al­so halt­ed any po­ten­tial com­pe­ti­tion un­til 2023 (de­spite the launch of Hu­mi­ra biosim­i­lars in Eu­rope in 2018), and that sup­pres­sion oc­curred even be­yond Ab­b­Vie’s own in­ter­nal pro­jec­tions.

In Feb­ru­ary 2014, ac­cord­ing to the com­mit­tee re­port, Ab­b­Vie ex­ec­u­tives cir­cu­lat­ed a pre­sen­ta­tion on “US Hu­mi­ra Biosim­i­lar Ero­sion” that pro­ject­ed that three to five biosim­i­lar com­peti­tors would en­ter the mar­ket by the first quar­ter of 2017.

What’s more, Ab­b­Vie’s patent on Hu­mi­ra’s ac­tive in­gre­di­ent ex­pired on De­cem­ber 31, 2016.

“At that time, com­peti­tors should have been free to en­ter the mar­ket. How­ev­er, the com­pa­ny ex­ploit­ed the patent sys­tem to ob­tain or ap­ply for over 200 ad­di­tion­al patents on Hu­mi­ra to block biosim­i­lar com­pe­ti­tion,” the re­port says.

Am­gen’s block­buster bi­o­log­ic En­brel, which won’t see biosim­i­lar com­pe­ti­tion in the US un­til 2029, is al­so one of Hu­mi­ra’s top com­peti­tors, and the com­mit­tee showed how the two com­pa­nies raised the prices of their drugs in lock-step with each oth­er.

“In­ter­nal Ab­b­Vie doc­u­ments ob­tained by the Com­mit­tee re­veal that the com­pa­ny viewed Am­gen’s price in­creas­es as pro­vid­ing cov­er for its own price in­creas­es. For ex­am­ple, one com­pa­ny ex­ec­u­tive re­port­ed to the cur­rent CEO and then-Ex­ec­u­tive Vice Pres­i­dent Richard Gon­za­lez that it was a ‘Great week-end’ af­ter learn­ing that Am­gen had in­creased the price of En­brel on Jan­u­ary 20, 2012, to $25,150 an­nu­al­ly. The email thread not­ed that ear­li­er that month, Ab­b­Vie had in­creased the price of Hu­mi­ra to $24,913 an­nu­al­ly. In Ju­ly, Ab­b­Vie would top Am­gen again by rais­ing the price of Hu­mi­ra to $26,632. Less than 3 weeks lat­er, Am­gen fol­lowed suit with an­oth­er price in­crease,” the re­port says.

Has the mo­ment fi­nal­ly ar­rived for val­ue-based health­care?

RBC Capital Markets’ Healthcare Technology Analyst, Sean Dodge, spotlights a new breed of tech-enabled providers who are rapidly transforming the way clinicians deliver healthcare, and explores the key question: can this accelerating revolution overturn the US healthcare system?

Key points

Tech-enabled healthcare providers are poised to help the US transition to value, not volume, as the basis for reward.
The move to value-based care has policy momentum, but is risky and complex for clinicians.
Outsourced tech specialists are emerging to provide the required expertise, while healthcare and tech are also converging through M&A.
Value-based care remains in its early stages, but the transition is accelerating and represents a huge addressable market.

FDA ad­vi­sors unan­i­mous­ly rec­om­mend ac­cel­er­at­ed ap­proval for Bio­gen's ALS drug

A panel of outside advisors to the FDA unanimously recommended that the agency grant accelerated approval to Biogen’s ALS drug tofersen despite the drug failing the primary goal of its Phase III study, an endorsement that could pave a path forward for the treatment.

By a 9-0 vote, members of the Peripheral and Central Nervous System Drugs Advisory Committee said there was sufficient evidence that tofersen’s effect on a certain protein associated with ALS is reasonably likely to predict a benefit for patients. But panelists stopped short of advocating for a full approval, voting 3-5 against (with one abstention) and largely citing the failed pivotal study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.

Sanofi, Re­gen­eron boast PhI­II win with Dupix­ent in COPD, clear­ing first bar for ex­pan­sion

Dupixent, the blockbuster anti-inflammatory drug from Sanofi and Regeneron, has cleared a high-stakes Phase III study in chronic obstructive pulmonary disease, the companies announced Thursday morning.

If they hold up in a second, identical trial, the data pave the way for Dupixent to become the first biologic to treat patients whose COPD remains uncontrolled despite being on maximal standard-of-care inhaled therapy — the patient population studied in the pivotal program. The companies had spotlighted this as a key readout as they look to expand the Dupixent franchise and explore its full potential.

Chat­G­PT with phar­ma da­ta de­buts for med­ical meet­ings, be­gin­ning with AACR

What do you get when you combine ChatGPT generative AI technology with specific pharma and clinical datasets? A time-saving tool that can answer questions about medical conference abstracts and clinical findings in seconds in one new application from ZoomRx called FermaGPT.

ZoomRx is debuting a public version of its generative AI product specifically for medical conferences beginning this week for the upcoming American Association for Cancer Research (AACR) annual meeting that runs April 14-19.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.

Alaa Halawa, executive director at Mubadala’s US venture group

The ven­ture crew at Mubadala are up­ping their biotech cre­ation game, tak­ing care­ful aim at a new fron­tier in drug de­vel­op­ment

It started with a cup of coffee and a slow burning desire to go early and long in the biotech creation business.

Wrapping up a 15-year discovery stint at Genentech back in the summer of 2021, Rami Hannoush was treated to a caffeine-fueled review of the latest work UCSF’s Jim Wells had been doing on protein degradation — one of the hottest fields in drug development.

“Jim and I have known each other for the past 15 years through Genentech collaborations. We met over coffee, and he was telling me about this concept of the company that he was thinking of,” says Hannoush. “And I got immediately intrigued by it because I knew that this could open up a big space in terms of adding a new modality in drug discovery that is desperately needed in pharma.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

In­cyte wins ac­cel­er­at­ed ap­proval for PD-1 in rare skin can­cer

Incyte touted an accelerated approval for its PD-1 retifanlimab in a rare skin cancer on Wednesday, roughly a year and a half after the drug suffered a rejection in squamous cell carcinoma of the anal canal (SCAC).

Retifanlimab, marketed as Zynyz, was approved for metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a fast-growing skin cancer typically characterized by a single, painless nodule. It’s roughly 40 times rarer than melanoma, according to the nonprofit Skin Cancer Foundation — but incidence is growing, particularly among older adults, Incyte said in its announcement.

FDA re­jects Ab­b­Vie's in­fu­sion ther­a­py for Parkin­son's, re­quests more in­fo on pump de­vice

The FDA rejected AbbVie’s 24-hour infusion therapy for Parkinson’s, saying it needs more information on a device used to administer the treatment before it can clear it.

The Chicago-area drugmaker said in a press release that the complete response letter from the agency didn’t include any requests for more efficacy or safety trials related to the drug, known as ABBV-951. The company said it aims to “resubmit the NDA as soon as possible.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.

A new study finds that many patient influencers are sharing prescription drug experiences along with health information.

So­cial me­dia pa­tient in­flu­encers ‘danc­ing in the gray’ of phar­ma mar­ket­ing, more clar­i­ty need­ed, re­searcher says

It’s no surprise that patient influencers are talking about their health conditions on social media. However, what’s less clear is what role pharma companies are playing, how big the patient influencer industry is, and just how is information about prescription drugs from influencers relayed — and received — on social media.

While University of Colorado associate professor Erin Willis can’t answer all those questions, she’s been researching the issue for several years and recently published new research digging into the communication styles, strategies and thinking of patient influencers, many of whom partner with pharma companies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.

Drug short­age so­lu­tions brought be­fore Sen­ate Home­land Se­cu­ri­ty com­mit­tee

With more than 300 active drug shortages, the Senate Committee on Homeland Security and Governmental Affairs had its hands full on Wednesday with multiple experts testifying on drug shortages and possible solutions.

A picture of the shortage situation. presented by Erin Fox, an adjunct professor at the College of Pharmacy at the University of Utah, explained how some patients have died due to drug shortages, including with medication errors when substitutes were dosed incorrectly or when an emergency product was not available.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.